Skip to content

CRP /albumin Ratio and Neutrophil Lymphocyte Ratio in Predicting Activity in IBD Patients

CRP/ Albumin Ratio and Neutrophil Lymphocyte Ratio in Predicting Activity in IBD Patients

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06750315
Enrollment
35
Registered
2024-12-27
Start date
2025-01-01
Completion date
2025-12-01
Last updated
2024-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Disease (IBD)

Keywords

CRP/ALB ratio, N/L ratio

Brief summary

This study aimed to assess the clinical utility of the NLR (neutrophil lymphocyte ratio) and CRP Albumin ratio in predicting activity of IBD Patients in assiut university

Detailed description

IBD definition term for two conditions (Crohn's disease and ulcerative colitis) is a chronic idiopathic inflammatory disease affecting the large intestine. It is characterized by relapsing mucosal inflammation. The aim of treatment is to induce and maintain disease remission. Assessing disease activity may help in optimizing the management of IBD patients. The neutrophil-to-lymphocyte ratio (NLR) is a simple index that can be calculated from the results of ordinary blood tests; it is calculated from a blood sample by dividing the absolute neutrophil count by the absolute lymphocyte count . As the NLR can reflect the systemic status of inflammation or immune response. The underlying mechanism that the NLR was a predictor of clinilcal relapse in UC patients with Mucosal healing remains poorly understood. Neutrophils induce cytotoxicity and inflammation in UC. A high NLR value may be due to high activity in UC and lowered mucosal barrier function, which may lead to the migration of neutrophils through the gut microbiota . CRP is routinely used as a surrogate measure of intestinal inflammation and as a prognostic measure of nonresponse to medical therapy and colectomy in patients with IBD.

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients more than 18 years newly diagnosed as IBD \-

Exclusion criteria

* Patients Not DM Not cardiac failure Not Liver failure No malignancy

Design outcomes

Primary

MeasureTime frameDescription
C-reactive protein /albumin ratio and neutrophil lymphocyte ratio in predicting activity in Inflammatory Bowel Disease Patients1 yearsNeutrophil lymphocyte ratio and CRP/Albumin ratio in detecting activity in IBD Patients.

Countries

Egypt

Contacts

Primary ContactAmira Mohamed Ali Ahmed
am3859282@gmail.com01090176978

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026